Tag: prospectus

Atlanta, GA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCQB: RHEP) (OTCQB: RHEPA) and SunLink Health Systems, Inc. (“SunLink”) (NYSE American: SSY) jointly announced today that, at special meetings of their respective shareholders each held on August 4, 2025, Regional shareholders and SunLink shareholders approved the merger of SunLink with and into Regional, with Regional as the surviving corporation pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of April 14, 2025, as amended, by and between Regional and SunLink. The SunLink shareholders also approved at their special meeting, on a non-binding advisory basis, the SunLink merger-related compensation proposal. The closing of the proposed merger remains subject to customary closing conditions.

MIDLAND, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Viper Energy, Inc., (NASDAQ:VNOM) (“Viper” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced financial and operating results for the second quarter ended June 30, 2025.

PALM BEACH, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- New America Acquisition I Corp. ("NAA" or the "SPAC"), a blank check company targeting businesses with a focus on American values and priorities, announced today that it has filed a registration statement on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") in connection with a proposed initial public offering of its units. The Florida-based company plans to raise $300 million by offering 30 million units at $10 per unit. Each unit consists of one share of Class A common stock and one-half of a warrant, with each whole warrant exercisable for one share of Class A common stock at $11.50 per share.

WHEATON, Ill., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Innovator Capital Management, LLC (Innovator) announces that the net asset value (NAV) per share of the Innovator International Developed Power Buffer ETF™ (NYSE Arca: IAUG) for July 31, 2025, was adjusted by the amount indicated below on August 1, 2025. This adjustment is a result of an error in calculating IAUG’s NAV.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.